Juan Morote, Hayley Pye, Miriam Campistol, Anna Celma, Lucas Regis, Maria Semidey, Ines de Torres, Richard Mast, Jacques Planas, Anna Santamaria, Enrique Trilla, Alcibiade Athanasiou, Saurabh Singh, Susan Heavey, Urszula Stopka-Farooqui, Alex Freeman, Aiman Haider, Ralph Schiess, Hayley C Whitaker, Shonit Punwani, Hashim U Ahmed, Mark Emberton
OBJECTIVES: The use of mpMRI has been a significant advance in the diagnosis of clinically significant prostate cancer (ISUP Grade Group ≥2, csPCa) and is recommended in most current guidelines. Proclarix® is a novel CE-marked biomarker test aiding in the identification of csPCa. The aim of the study was the assessment of the clinical performance of Proclarix alone or in combination with mpMRI to predict csPCa. PATIENTS AND METHODS: The study included blood samples from 721 men undergoing mpMRI followed by biopsy at University College London (UCL), London, and Vall d'Hebron University Hospital, Barcelona...
March 1, 2023: BJU International